ReviewClinical and translational science2023
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence.
Review in Clinical and translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06192589 (Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions), which is not on this map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Who cites it
48 citing papers in PubMed, 79 citations in OpenAlex.
- Medicinal cannabis plant extract (NTI164) modifies epigenetic, ribosomal, and immune pathways in paediatric acute-onset neuropsychiatric syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Trial
- An open-label feasibility trial of transdermal cannabidiol for hand osteoarthritis.Scientific reports · 2024Trial
- (+)-Trans-Cannabidiol Is an Agonist at Human CBPharmacology research & perspectives · 2026Article
- Repeated whole-body inhalation of cannabidiol vapor induces progressive pulmonary inflammatory and vascular remodeling without systemic toxicity in Sprague-Dawley rats.Veterinary world · 2026Article
- Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3Epilepsia open · 2026Article
- Toxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products.Toxicology reports · 2026Review
- High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial.EClinicalMedicine · 2026Article
- Cannabinoid efficacy for pain: dose, chronicity and route.Frontiers in neuroscience · 2026Review
- Bioinformatics differential expression analysis of the effect of cannabidiol in chronic myeloid leukaemia cell line.Global medical genetics · 2025Article
- Placebo effects in a RCT assessing 30 days of low dose Cannabidiol (CBD) treatment for psychological distress in stressed students at risk for depression.Journal of cannabis research · 2025Article
- The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial.Sports medicine - open · 2025Article
- Cannabinoid Distribution and Clearance in Feeding Spent Hemp Biomass to Dairy Cows and the Potential Exposure to ΔJournal of agricultural and food chemistry · 2025Article
- Cannabidiol abrogates cue-induced anxiety associated with normalization of mitochondria-specific transcripts and linoleic acid in the nucleus accumbens shell.Molecular psychiatry · 2025Article
- Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- An analysis of the cultivation, consumption and composition of home-grown cannabis following decriminalisation in the Australian Capital Territory.Scientific reports · 2025Article
- The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors.CNS drugs · 2025Review
- A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims.Nutrients · 2025Review
- Cannabidiol use among elite-level Canadian athletes: the pursuit of improved sleep, pain relief, and enhanced recovery.Frontiers in nutrition · 2025Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global interest in the non-intoxicating cannabis constituent, cannabidiol (CBD), is increasing with claims of therapeutic effects across a diversity of health conditions. At present, there is sufficient clinical trial evidence to support the use of high oral doses of CBD (e.g., 10-50 mg/kg) in treating intractable childhood epilepsies. However, a question remains as to whether "low-dose" CBD products confer any therapeutic benefits. This is an important question to answer, as low-dose CBD products are widely available in many countries, often as nutraceutical formulations. The present review therefore evaluated the efficacy and safety of low oral doses of CBD. The review includes interventional studies that measured the clinical efficacy in any health condition and/or safety and tolerability of oral CBD dosed at less than or equal to 400 mg per day in adult populations (i.e., ≥18 years of age). Studies were excluded if the product administered had a Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.